HK1165206A1 - Biomarker for selecting patients and related methods - Google Patents

Biomarker for selecting patients and related methods

Info

Publication number
HK1165206A1
HK1165206A1 HK12105900.4A HK12105900A HK1165206A1 HK 1165206 A1 HK1165206 A1 HK 1165206A1 HK 12105900 A HK12105900 A HK 12105900A HK 1165206 A1 HK1165206 A1 HK 1165206A1
Authority
HK
Hong Kong
Prior art keywords
biomarker
related methods
selecting patients
patients
selecting
Prior art date
Application number
HK12105900.4A
Other languages
English (en)
Chinese (zh)
Inventor
Bruce Acres
Benot Grellier
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of HK1165206A1 publication Critical patent/HK1165206A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12105900.4A 2009-07-10 2012-06-15 Biomarker for selecting patients and related methods HK1165206A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305672 2009-07-10
PCT/EP2010/059635 WO2011003905A1 (en) 2009-07-10 2010-07-06 Biomarker for selecting patients and related methods

Publications (1)

Publication Number Publication Date
HK1165206A1 true HK1165206A1 (en) 2012-09-28

Family

ID=42634974

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105900.4A HK1165206A1 (en) 2009-07-10 2012-06-15 Biomarker for selecting patients and related methods

Country Status (20)

Country Link
US (1) US9261512B2 (da)
EP (1) EP2452194B1 (da)
JP (1) JP5650212B2 (da)
KR (1) KR20120089619A (da)
CN (1) CN102483405B (da)
AU (1) AU2010270313B2 (da)
BR (1) BR112012000522A2 (da)
CA (1) CA2767458A1 (da)
DK (1) DK2452194T3 (da)
ES (1) ES2558729T3 (da)
HK (1) HK1165206A1 (da)
HU (1) HUE028240T2 (da)
IL (1) IL216083A (da)
MX (1) MX337287B (da)
NZ (1) NZ596325A (da)
RU (1) RU2552292C2 (da)
SG (1) SG176619A1 (da)
TW (1) TWI529392B (da)
WO (1) WO2011003905A1 (da)
ZA (1) ZA201200110B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617200T3 (es) 2011-09-15 2017-06-15 Nogra Pharma Limited Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7
JP2015512892A (ja) * 2012-03-13 2015-04-30 アッヴィ・インコーポレイテッド Ｖ１ｂアンタゴニスト療法について対象を選択または同定するための方法
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
DK3011059T3 (da) 2013-06-20 2019-05-13 Immunexpress Pty Ltd Biomarkør-identifikation
DK3103046T3 (da) 2014-02-06 2020-06-02 Immunexpress Pty Ltd Biomarkør-signaturfremgangsmåde og apparater og kits deraf
FR3072973B1 (fr) * 2017-10-26 2022-02-11 Univ Pierre Et Marie Curie Paris 6 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
RU2705398C1 (ru) * 2018-08-17 2019-11-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) Способ прогнозирования эффективности применения средства для повышения относительного содержания высокодифференцированных клеток в аденокарциноме молочной железы и композиция для его осуществления

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
CA2190290C (en) 1994-05-13 2011-07-05 Michael J. Mastrangelo A method of inducing an immune response using vaccinia virus recombinants
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
WO1998004727A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO1998039017A1 (fr) 1997-03-07 1998-09-11 Akira Hayashi Agent immunotherapeutique indique pour le cancer contenant un composant nucleoide de bacterie comme principe actif
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
ES2220448T3 (es) 1999-02-04 2004-12-16 Geron Corporation Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa.
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP2325321A1 (en) 1999-05-28 2011-05-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6110135A (en) 1999-06-17 2000-08-29 Becton, Dickinson And Company Elbow brace with movable support
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US8198400B2 (en) 2001-03-27 2012-06-12 Oncothyreon, Inc. Vaccine for modulating between T1 and T2 immune responses
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
US6928476B2 (en) 2002-08-23 2005-08-09 Mirra, Inc. Peer to peer remote data storage and collaboration
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
JP2007512489A (ja) 2003-11-24 2007-05-17 アルーマナ、マイクロウ、エルエルシー 可変容量形コンプレッサの制御に適したマイクロバルブ・デバイス
WO2007015171A2 (en) 2005-06-28 2007-02-08 Biomira, Inc. Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
PL2212345T3 (pl) 2007-11-19 2016-07-29 Transgene Sa Onkolityczne wektory pokswirusowe
CA2705873C (en) 2007-11-19 2012-06-12 Philippe Erbs Poxviral oncolytic vectors
US20120028279A1 (en) 2009-03-24 2012-02-02 Bruce Acres Biomarker for monitoring patients

Also Published As

Publication number Publication date
MX337287B (es) 2016-02-22
AU2010270313B2 (en) 2014-05-22
CN102483405B (zh) 2015-12-02
TWI529392B (zh) 2016-04-11
CN102483405A (zh) 2012-05-30
TW201105970A (en) 2011-02-16
IL216083A (en) 2015-04-30
BR112012000522A2 (pt) 2016-02-16
US9261512B2 (en) 2016-02-16
RU2012103932A (ru) 2013-08-20
HUE028240T2 (en) 2016-12-28
EP2452194B1 (en) 2015-11-11
JP5650212B2 (ja) 2015-01-07
ES2558729T3 (es) 2016-02-08
NZ596325A (en) 2013-11-29
AU2010270313A1 (en) 2011-11-24
WO2011003905A1 (en) 2011-01-13
MX2012000509A (es) 2012-02-13
CA2767458A1 (en) 2011-01-13
JP2012533052A (ja) 2012-12-20
KR20120089619A (ko) 2012-08-13
ZA201200110B (en) 2012-10-31
DK2452194T3 (da) 2015-11-30
US20120115249A1 (en) 2012-05-10
RU2552292C2 (ru) 2015-06-10
IL216083A0 (en) 2012-01-31
SG176619A1 (en) 2012-01-30
EP2452194A1 (en) 2012-05-16

Similar Documents

Publication Publication Date Title
GB0906458D0 (en) Macromolecules for diagnosis and prognosis
EP2405805A4 (en) METHODS AND APPARATUS FOR ASSESSING PHYSIOLOGICAL CONDITIONS
EP2416657A4 (en) COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
GB0909645D0 (en) Methods
GB0907350D0 (en) Methods
SG10201405455UA (en) Cells and methods for obtaining them
EP2493494A4 (en) METHODS AND NECESSARY TO PREVENT HYPOGLYCEMIA
GB0901001D0 (en) Methods
HK1165206A1 (en) Biomarker for selecting patients and related methods
EP2324768A4 (en) TOMOGRAPHIC PROCEDURE
GB0912685D0 (en) Methods
GB0921329D0 (en) Biomarker
GB0900555D0 (en) New methods
EP2389590A4 (en) INSTRUMENT ROTARY TABLE AND METHOD FOR ITS USE
GB0912159D0 (en) Methods
GB0912394D0 (en) Screening methods
HK1163246A1 (en) Biomarker for monitoring patients
HK1161644A1 (en) Biomarker for monitoring patients
IL217333A0 (en) Biomarker
EP2470022A4 (en) COMPOUNDS AND METHODS
GB0909380D0 (en) Method and use
ZA201008471B (en) Biomarker for selecting patients and related methods
GB0912175D0 (en) Biomarker
EP2403963A4 (en) BIOMARKER AND TREATMENT FOR CANCER
GB0903348D0 (en) Compounds and methods relating thereto

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190708